Research Lab Update

Update March 18: Message to PLM Research Faculty: NIH COVID-19 announcements and PSOM-mandated lab ramp-down.

Research Lab Update

Update March 16: Message to PLM Research Faculty regarding lab ramp-down as mandated by PSOM leadership.

CRISPR-engineered T cells in Patients with Refractory Cancer

Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published in Science by researchers from the Abramson Cancer Center.

CRISPR-engineered T cells in patients with refractory cancer

Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published by researchers from the Abramson Cancer Center.

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Penn study shows potential of interferon pathway as biomarker, therapeutic target

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer